ABVC BioPharma, a clinical-stage biopharmaceutical company specializing in ophthalmology, CNS, and oncology/hematology, has announced a significant global licensing deal for its medical device, Vitargus. The company, along with its subsidiary BioFirst Corporation, entered into an agreement with ForSeeCon Eye Corporation (FEYE) to license the Ophthalmology pipeline, including the highly valued Vitargus device. The licensing income from this deal amounts to $33.5 million, with potential royalties reaching up to $60 million.
Vitargus, valued at $187 million by a third-party valuer, is a medical device developed by ABVC BioPharma that aims to provide therapeutic solutions for various eye-related conditions. This global licensing agreement entails FEYE obtaining the rights for the clinical trial, registration, manufacturing, supply, and distribution of the licensed products.
This milestone represents a major success for ABVC BioPharma as it secures a substantial sum in licensing income and the potential for lucrative royalties. It also signifies the recognition of the value and potential of the Vitargus device in the ophthalmology field. ABVC BioPharma’s focus on developing solutions for ophthalmology, CNS, and oncology/hematology has positioned the company as a key player in these therapeutic areas.
The licensing agreement with FEYE opens up new avenues for ABVC BioPharma to expand its reach and deliver its innovative medical device to a wider patient population. FEYE’s involvement in the clinical trial, manufacturing, supply, and distribution of Vitargus will ensure its availability in various markets across the globe.
This licensing deal comes at a time when ABVC BioPharma has experienced a significant decline in revenue. In the corresponding period, the company’s revenue deteriorated by -98.05% year on year, with a sequential decline of -95.24%. However, this agreement has the potential to provide a much-needed boost to the company’s financial performance.
Comments